TEVA
Teva Pharma Industries Ltd
36.50$
-0.6%
vs. previous close
Closing price · As of: Aug 13, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 27.1% | 28.7% | 28.7% | 28.1% | 29.5% | 31.9% | 30.0% | 31.4% | 32.0% | 34.2% | 34.2% | 34.5% | |
| 5.3% | 7.4% | 7.0% | 5.5% | 7.9% | 8.4% | 4.4% | 5.4% | 5.5% | 8.7% | 9.3% | 9.2% | |
| 5.3% | 7.4% | 7.0% | 5.5% | 7.9% | 8.4% | 4.4% | 5.4% | 5.5% | 8.7% | 9.3% | 9.2% | |
| 8.0% | 7.8% | 8.1% | 9.1% | 8.3% | 7.8% | 8.8% | 8.9% | 9.6% | 9.1% | 8.5% | 8.8% | |
| 9.6% | 9.2% | 9.2% | 9.5% | 9.5% | 7.6% | 8.5% | 8.7% | 8.3% | 7.8% | 7.9% | 8.1% | |
| 14.3% | – | – | – | – | – | – | – | – | – | – | – | |
| 40.1% | 39.5% | 39.8% | 39.9% | 38.6% | 38.5% | 40.3% | 39.7% | 40.0% | 39.3% | 39.5% | 39.7% | |
| 13.1% | 12.4% | 11.8% | 11.7% | 11.4% | 11.2% | 10.9% | 10.3% | 9.9% | 9.3% | 9.0% | 8.6% | |
| 82.2% | 81.3% | 82.4% | 84.1% | 84.7% | 85.5% | 83.7% | 83.0% | 81.8% | 80.6% | 79.4% | 80.5% | |
| 27.1% | 28.2% | 32.2% | 31.5% | 33.0% | 32.5% | 29.0% | 29.6% | 28.8% | 33.0% | 33.8% | 39.3% | |
| 3.5% | 3.8% | 7.2% | 5.1% | 6.2% | 4.5% | 1.1% | 1.2% | 0.1% | 4.5% | 6.5% | 11.3% | |
| 5.4% | 6.0% | 5.7% | 5.7% | 5.7% | 5.6% | 6.0% | 6.2% | 5.9% | 6.2% | 6.5% | 6.8% | |
| 43.9% | 41.8% | 38.8% | 40.0% | 39.3% | 40.7% | 42.2% | 41.8% | 42.1% | 36.8% | 35.0% | 30.3% | |
| 16.5% | 17.3% | 17.0% | 15.4% | 14.5% | 13.7% | 16.3% | 17.0% | 18.2% | 19.4% | 20.5% | 19.5% | |
| -33.0% | -31.1% | -32.0% | -35.1% | -35.8% | -38.6% | -38.9% | -36.6% | -35.7% | -33.8% | -33.5% | -35.0% | |
| 2.7% | 2.6% | 2.6% | 2.7% | 2.7% | 2.9% | 3.0% | 2.9% | 2.9% | 2.9% | 2.9% | 3.0% |
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.